Significantly Prolonged Prothrombin Time and Activated Partial Thromboplastin Time with no Bleeding Tendency: A Patient with Lupus Anticoagulant–Hypoprothrombinemia Syndrome Positive for Immunoglobulin M Anti-Phosphatidylserine/Prothrombin complex Antibodies

Yang Fei; Ning Tang; Hui Zhang; Guo Li; Hongbo Zhang; Chi Zhang

doi:10.1055/s-0039-3402477

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2020; 46(04): 507-511
DOI: 10.1055/s-0039-3402477

Letter to the Editor

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Significantly Prolonged Prothrombin Time and Activated Partial Thromboplastin Time with no Bleeding Tendency: A Patient with Lupus Anticoagulant–Hypoprothrombinemia Syndrome Positive for Immunoglobulin M Anti-Phosphatidylserine/Prothrombin complex Antibodies

Yang Fei‡^*

¹Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

,

Ning Tang‡^*

¹Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

,

Hui Zhang

¹Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

,

Guo Li

¹Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

,

Hongbo Zhang

¹Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

,

Chi Zhang

¹Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

› Author Affiliations

Abstract

Full Text

References

References
1 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
2 Mulliez SM, De Keyser F, Verbist C. , et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Lupus 2015; 24 (07) 736-745
3 Mazodier K, Arnaud L, Mathian A. , et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore) 2012; 91 (05) 251-260
4 Islam MA, Alam F, Sasongko TH, Gan SH. Antiphospholipid antibody-mediated thrombotic mechanisms in antiphospholipid syndrome: towards pathophysiology-based treatment. Curr Pharm Des 2016; 22 (28) 4451-4469
5 Meroni PL, Ronda N, De Angelis V, Grossi C, Raschi E, Borghi MO. Role of anti-beta2 glycoprotein I antibodies in antiphospholipid syndrome: in vitro and in vivo studies. Clin Rev Allergy Immunol 2007; 32 (01) 67-74
6 Lim W. Complement and the antiphospholipid syndrome. Curr Opin Hematol 2011; 18 (05) 361-365
7 Male C, Lechner K, Eichinger S. , et al. Clinical significance of lupus anticoagulants in children. J Pediatr 1999; 134 (02) 199-205
8 Bauersachs RM, Dudenhausen J, Faridi A. , et al; EThIG Investigators. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007; 98 (06) 1237-1245
9 Pengo V, Tripodi A, Reber G. , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
10 Tripodi A, Chantarangkul V. Lupus anticoagulant testing: activated partial thromboplastin time (APTT) and silica clotting time (SCT). Methods Mol Biol 2017; 1646: 177-183
11 Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta MA. Seronegative antiphospholipid syndrome. Rheumatology (Oxford) 2013; 52 (08) 1358-1367
12 Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014; 111 (02) 354-364
13 Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983; 61 (04) 684-692
14 Jin J, Zehnder JL. Prozone effect in the diagnosis of lupus anticoagulant for the lupus anticoagulant-hypoprothrombinemia syndrome. Am J Clin Pathol 2016; 146 (02) 262-267
15 Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2010; 8 (12) 2828-2831
16 Ieko M, Yoshida M, Naito S, Ohmura K, Takahashi N. Lupus anticoagulant-hypoprothrombinemia syndrome and similar diseases: experiences at a single center in Japan. Int J Hematol 2019; 110 (02) 197-204
17 Hoxha A, Ruffatti A, Mattia E. , et al. Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clin Chem Lab Med 2015; 53 (08) 1265-1270
18 Pregnolato F, Chighizola CB, Encabo S. , et al. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. Immunol Res 2013; 56 (2-3): 432-438